Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Notes Theoretical Cancer Risk For Centocor’s Ustekinumab

This article was originally published in The Pink Sheet Daily

Executive Summary

MAb for psoriasis has favorable odds for a June 17 recommendation by advisory panel, analysts say.

You may also be interested in...



FDA Panel Unanimously Recommends Centocor’s Ustekinumab

But Dermatologic and Ophthalmic Drugs panel says the proposal for long-term safety follow-up is inadequate.

FDA Panel Unanimously Recommends Centocor’s Ustekinumab

But Dermatologic and Ophthalmic Drugs panel says the proposal for long-term safety follow-up is inadequate.

Promacta, Doribax Applications Get Advisory Committee Reviews

Amgen’s Enbrel will also be reviewed for a pediatric psoriasis indication.

Related Content

Topics

UsernamePublicRestriction

Register

AP000801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel